---
title: "Lasso Regression for Oncology Utilization Management Applications"
subtitle: "A report on Lasso Regression for data science projects - Fall 2025"
author: "Vijayavel Mohanam, Jennifer Nesbit and Sassou Khabou (Advisor: Dr. Cohen)"
date: '`r format(Sys.Date(), "%Y-%m-%d")`'
format:
  html:
    code-fold: true
course: Capstone Projects in Data Science
bibliography: references.bib # file contains bibtex for references
#always_allow_html: true # this allows to get PDF with HTML features
self-contained: true
execute: 
  warning: false
  message: false
editor: 
  markdown: 
    wrap: 72
---

[Slides:](slides.html){target="_blank"}

[//]: ::: callout-note
[//]: **Week 01:** This is our first week as group, we are trying to compile a summary of introductions!

[//]: **Week 02:** We tried to add more articles from our research and narrowing on a particular dataset!

[//]:  **Week 03:** Downloaded USA cancer dataset, exploring attributes and records for our study!

[//]: **Week 04:** Analysed the variables, selected and recoded for our model!

[//]: **Week 05:** Refined the variables, as metadata and data were not matching!

[//]: **Week 06:** Started coding in R studio!

[//]: **Week 07:** Applied Lasso regression on two outcome - radiation and chemotherapy!

[//]: **Week 08:** Accessed the results and was able to interpret back to the clinical value!

[//]: **Week 09:** Added conclusion and getting ready for our presentation!

[//]: Nice effort!
[//]: :::

## Introduction

Least Absolute Shrinkage and Selection Operator (Lasso) and Ridge regression are both regularization techniques used to prevent overfitting and multicollinearity in linear regression models by adding a penalty term to the loss function. The Lasso regression method was first introduced by Tibshirani in 1996 and has become a widely used method in both statistical modeling and machine learning. Lasso regression uses L1 regularization, which adds a penalty proportional to the sum of the absolute values of the coefficients, whereas Ridge uses L2 regularization, which adds a penalty proportional to the sum of the squared coefficients. An additional regularization technique called Elastic Net regression, combines both Lasso and Ridge. This technique is useful when there are many correlated features. The L1 penalty used with Lasso shrinks some coefficients to zero which allows for automated selection while also reducing model complexity. Overall Lasso is able to combine both predictive accuracy with interpretability. 

Lasso has demonstrated its versatile and practical uses as it has been applied across diverse applications. In healthcare, Lasso has been used to predict prevalence of child malaria Aheto et al., 2021[@aheto], stroke risk in hypertensive patients Huang & Liu, 2025[@huang] and adverse drug reactions in polypharmacy Sommer et al., 2024 [@sommer]. These studies all highlight the ability for Lasso to produce models with fewer predictors while maintaining strong performance and often outperforming Ridge regression models in interpretability. Lasso has also been applied to clinical diagnostics, specifically improving disease classification for glaucoma progression Fujino et al., 2015 [@fujino] and differentiating between hematologic cancers Amaador et al., 2022[@amaador]. Another medical related paper on gastroenterology (Ali, H et al., 2023)[@ali] also applied Lasso to select key predictors and remove insignificant predictors by setting their coefficients to zero. These applications demonstrate the ability of Lasso to enhance decision making with streamlined models.

Lasso regression has also been proven as an effective methodology in economics and finance. Specifically, in predicting corporate bankruptcy Pereira et al., 2016[@pereira] and analyzing housing price network connectedness Gabauer et al., 2024[@gabauer]. Lasso has also been used for technology applications such as supporting innovations specifically with sensor selection for wearable respiratory monitoring devices Laufer et al., 2023 [@laufer] and improved interpretability with decision tree models Czajkowski et al., 2023 [@czajkowski].

Research has been done to compare the use of Lasso as a methodology to multiple related techniques such as Ridge and Elastic Net. Studies have shown that Ridge regression sometimes outperforms Lasso when predictor variables are highly correlated. However, Lasso tends to be more valuable when only a few predictors are significant and applicable to the problem at hand Vidaurre et al., 2013[@vidaurre]. Overall, Lasso shows a consistent advantage with its ability to produce sparse, interpretable and efficient models making it an excellent tool for both modeling and research.

A principal advantage of Lasso (Least Absolute Shrinkage and Selection Operator) regression is its capacity for feature shrinkage and selection. As established in the seminal works by ‚ÄúIntroduction to the Lasso‚Äù (Gauraha, N, 2018)[@gauraha], selection of most relevant variables from a large set of clinical and pathological data while shrinking less important ones to zero(Li, Y., Bai. 2023)[@li] and ‚ÄúRegression Shrinkage and Selection Via the Lasso‚Äù (Robert Tibshirani. 1996)[@robert]. They also compare lasso regression to both ridge regression and subset selection. Unlike in ridge regression, where all parameters can only asymptotically approach zero, lasso regression allows some parameters to reach zero. These techniques are applied in Machine Learning for feature selection techniques in predictive modeling (R. Muthukrishnan and R. Rohini. 2016)[@muthu] .On the same lines, we can see how to handle zero inflated predictors(Mariella Gregorich et al., 2025)[@mari] handled by Lasso.

After considering the multiple impactful applications of Lasso regression, this study will apply Lasso to a real-world healthcare problem using the Surveillance, Epidemiology and End Results (SEER) database. Specifically, we aim to develop predictive models that will estimate the likelihood of various cancer treatments such as chemotherapy, radiation therapy or surgery based on patient demographics and clinical characteristics. We will leverage the ability of Lasso to select the most influential factors driving treatment decisions while automatically excluding less informative predictors. The ultimate goal of this application is to support utilization management processes by streamlining treatment approval pathways and expediting patient access to appropriate care. Through this study, we aim to demonstrate how Lasso regressive can serve as an effective tool for improving operational efficiency and decision making in oncology care.


## Data Exploration and Visualization




The data for this study was obtained from the SEER program of the [National Cancer Institute (NCI)](https://seer.cancer.gov/archive/manuals/2018/SPCSM_2018_maindoc.pdf). SEER[@seer] is a comprehensive population-based cancer registry within the United States that consists of a collection of detailed information on cancer incidence, patient demographics, tumor characteristics, treatment modalities and survival outcomes. The SEER dataset provides high quality, standardized data that allows for large-scale analyses of cancer patterns, treatments and outcomes across diverse populations in the United States. For this study we focused on female breast cancer cases (ICD O-3 site codes C50.0 - C50.9) from 2018 - 2022 and specific variables to indicate whether a patient received specific treatment such as surgery, radiation, chemotherapy, immunotherapy or hormone therapy based on the SEER treatment summary fields. This time period aligns with the period following SEER‚Äôs transition to the Extent of Disease (EOD) 2018 and Summary Stage 2018 systems. This time was chosen because these years provide the most consistent and comprehensive recording of tumor stage, biological markers and treatment variables. Using 2018 - 2022 ensures compatibility across staging and treatment codes while avoiding inconsistencies in earlier datasets.

We focused on variables that are clinically relevant and have been shown to influence treatment decisions in breast cancer. These variables have been categorized into three groups: treatment variables, tumor characteristics and patient demographics. Radiation therapy was identified using the variable Radiation recode and chemotherapy from Chemotherapy recode. These variables capture first-course treatments administered after diagnosis. Only first primary malignancies were included to avoid confounding from prior cancer diagnoses and treatments. Patients with missing or unknown key staging information were excluded. Each treatment variable was recoded into a binary outcome with 1 indicating that treatment was received and 0 indicating that treatment was not received or unknown. 

The tumor characteristic variables capture the biological and clinical features of each breast cancer case and are significant determinants of prognosis and treatment selection. Tumor size was included as a continuous numeric variable representing the largest tumor dimension in millimeters prior to treatment. Summary stage, based on the Combined Summary Stage with Expanded Regional Codes, categorized disease extent from in situ to distant spread, providing an overall measure of progression. Nodal involvement, recoded from the EOD Regional Nodes variable, was grouped into N0-N3 categories reflecting increasing lymphatic spread. Metastatic indicators for bone, brain, liver, lung and distant lymph nodes were each recoded as binary variables to identify the presence or absence of distant disease. Laterality identified the side of origin (left or right breast), while Clinical Grade summarized tumor differentiation as low, intermediate or high. Hormone receptor and HER2 status (ER, PR, HER2) were each treated as binary variables (positive or negative) and used to characterize molecular subtypes relevant to therapy decisions. Collectively, these variables provide a detailed picture of tumor biology and stage at diagnosis.

Patient demographic variables describe the population characteristics of the sample and help identify disparities in presentation or treatment. Age at diagnosis was grouped into 5-year intervals and treated as an ordinal categorical variable. Sex was coded as a binary variable (male/female). Race, Hispanic origin and the combined race/ethnicity recode were included as categorical variables to capture sociodemographic diversity and potential disparities. Marital status as diagnosis was collapsed into partnered versus unpartnered categories to assess social support influences. The type of reporting source identified the institution or data source contributing to each case and the year of diagnosis (2018-2022) was treated as a categorical variable. Overall, these demographic factors contextualize differences in clinical presentation and treatment patterns across the study population.


Table 1

***Treatment Variables***

|Variable Name|Description|Seer Codes (2018-2022)|Recoding for modeling|
|:------|:------ |:------------|:------------|
|Radiation recode|Radiation of the primary site|Beam radiation<BR> Radioactive implants (includes brachytherapy) (1988+)<BR>Refused (1988+)<BR>Combination of beam with implants or isotopes<BR>None/Unknown|Binary: <BR>1 = any radiation [Beam radiation Radioactive implants (includes brachytherapy) (1988+), Refused (1988+),<BR>Combination of beam with implants or isotopes]<BR>0 = no radiation or unknown [None/Unknown]|
|Chemotherapy recode|The chemotherapy given as a part of the first course of treatment or the reason that chemotherapy was not given.|Yes = patient had chemotherapy<BR>No/Unknown = no evidence of chemotherapy was found in the medical records examined|Binary: <BR>1 = any chemotherapy[Yes]<BR>0 = no chemotherapy [No/Unknown]|
|Sequence number|Describes the number and sequence of all reportable malignant, in situ, benign, and borderline primary tumors that occur over the lifetime of a patient.|One primary only <BR>1st of 2 or more primaries <BR>2nd of 2 or more primaries etc.|Filter data to only include ‚ÄúOne primary only‚Äù and ‚Äú1st of 2 or more primaries‚Äù|



Table 2

***Treatment Characteristics***

|Variable Name|Description|Seer Codes (2018-2022)|Recoding for modeling|
|:------|:------ |:------------|:------------|
|Tumor Size Summary (2016+)|Size of a solid primary tumor before any treatment|000 = No mass/tumor found<BR>001 = 1 mm or described as less than 1 mm (0.1 cm or less than 0.1 cm)<BR>002-988 = Exact size in millimeters (2 mm to 988 mm) (0.2 to 98.8 cm)<BR>989 = 989 millimeters or larger (98.9 cm or larger)<BR>990 = Microscopic focus or foci only and no size of focus is given<BR>998 = Alternate descriptions of tumor size for specific sites: Diffuse Breast (C50.0-C50.6, C50.8-C50.9)<BR>999 = Unknown; size not stated, Not documented in patient record, Size of tumor cannot be assessed, The only measurement(s) describes pieces or chips, Not applicable|Continuous numeric|
|Combined Summary Stage with Expanded Regional Codes (2004+)|Cancer staging system that categorizes the extent of cancer spread from its point of origin using a combination of clinical and pathological data.|In situ<BR>Localized only<BR>Regional by direct extension only <BR>Regional lymph nodes involved only<BR>Regional by both direct extension and lymph node involvement<BR>Distant site(s)/node(s) involved <BR>Unknown/unstaged/unspecified/DCO|Categorical: <BR>In situ<BR>Localized only<BR>Regional by direct extension only<BR>Regional lymph nodes involved only<BR>Regional by both direct extension and lymph node involvement<BR>Distant site(s)/node(s) involved<BR>Unknown/unstaged/unspecified/DCO|
|EOD Regional Nodes Recode (2018+)|Records the farthest regional lymph node chain involved by a tumor|000 = No clinical regional lymph node involvement<BR>030 = PATHOLOGICAL, ITCs only (malignant cell clusters no larger than 0.2 mm) in regional lymph node(s)<BR>050 = PATHOLOGICAL, Positive molecular findings by reverse transcriptase polymerase chain reaction (RT-PCR), no ITCs detected<BR>070 = No regional lymph node involvement pathologically (lymph nodes removed and pathologically negative) WITHOUT ITCs or ITC testing unknown<BR>100 = Micrometastasis, less than or equal to 2 mm, Axillary (level I and II) lymph node(s), ipsilateral, Detected by IHC or H&E (At least one micrometastasis greater than 0.2 mm or more than 200 cells), Micrometastasis, NOS<BR>150 = CLINICAL, Clinically positive movable axillary (level I and II) lymph node(s), ipsilateral, Positive needle core biopsy/FNA<BR>200 = PATHOLOGICAL, Positive axillary (level I and II) lymph node(s), ipsilateral, WITH more than micrometastasis (At least one metastasis greater than 2 mm, or size of metastasis not stated), WITHOUT internal mammary lymph node(s) or not stated<BR>250 = PATHOLOGICAL, Internal mammary node(s), ipsilateral, positive on sentinel node biopsy but not clinically apparent (No positive imaging or clinical exam) WITHOUT axillary lymph node(s), ipsilateral<BR>300 = PATHOLOGICAL, Internal mammary node(s), ipsilateral, positive on sentinel node biopsy but not clinically apparent (No positive imaging or clinical exam) WITH axillary lymph node(s), ipsilateral<BR>350 = CLINICAL, Fixed/matted ipsilateral axillary (level I and II)<BR>400 = CLINICAL, Internal mammary node(s), ipsilateral WITHOUT axillary (level I and II) lymph node(s), ipsilateral RN<BR>500 = Infraclavicular lymph node(s) (subclavicular) (level III axillary node(s)) (apical), ipsilateral WITH or WITHOUT axillary (level I and II) nodes(s) WITHOUT internal mammary node<BR>600 = Internal mammary node(s), ipsilateral, clinically apparent (On imaging or clinical exam) WITH axillary (level I, II, or III) lymph node(s), ipsilateral including infraclavicular<BR>700 = Supraclavicular node(s), ipsilateral<BR>800 = Regional lymph node(s), NOS, Lymph node(s), NOS<BR>999 = Unknown; regional lymph node(s) not stated, Regional lymph node(s) cannot be assessed, Not documented in patient record, Death Certificate Only|Categorical:<BR>N0 = 000, 030, 050, 070<BR>N1 = 100, 150, 200, 250, 300<BR>N2 = 350, 400<BR>N3 = 500, 600, 700<BR>NX = 800, 999|
|SEER Combined Mets at DX-bone (2010+)|This field identifies whether bone is an involved metastatic site.|No = no bone metastases<BR>Yes = yes distant bone metastases<BR>N/A Unknown|Binary: <BR>No = no bone metastases<BR>Yes = yes distant bone metastases<BR>*exclude N/A and Unknown|
|SEER Combined Mets at DX-brain (2010+)|This field identifies whether brain is an involved metastatic site.|No = no brain metastases<BR>Yes = yes distant brain metastases<BR>N/A Unknown|Binary: <BR>No = no brain metastases<BR>Yes = yes distant brain metastases<BR>*exclude N/A and Unknown|
|SEER Combined Mets at DX-liver (2010+)|This field identifies whether liver is an involved metastatic site.|No = no liver metastases<BR>Yes = yes distant liver metastases<BR>N/A Unknown|Binary: <BR>No = no liver metastases<BR>Yes = yes distant liver metastases<BR>*exclude N/A and Unknown|
|SEER Combined Mets at DX-lung (2010+)|This field identifies whether lung is an involved metastatic site.|No = no lung metastases<BR>Yes = yes distant lung metastases<BR>N/A Unknown|Binary: <BR>No = no lung metastases<BR>Yes = yes distant lung metastases<BR>*exclude N/A and Unknown|
|Mets at DX-Distant LN|This field identifies whether distant lymph node(s) are an involved metastatic site.|No = no distant lymph node metastases<BR>Yes = yes distant lymph node metastases<BR>N/A Unknown|Binary: <BR>No = no distant lymph node metastases<BR>Yes = yes distant lymph node metastases<BR>*exclude N/A and Unknown|
|Laterality|Describes the side of a paired organ or side of the body on which the reportable tumor originated.|Right - origin of primary <BR>Left - origin of primary<BR>Only one side - side unspecified<BR>Bilateral, single primary <BR>Paired site, but no information concerning laterality|Categorical:<BR>Right - origin of primary<BR>Left - origin of primary<BR>Bilateral, single primary <BR>*exclude ‚ÄúOnly one side - side unspecified Bilateral, single primary‚Äù and ‚ÄúPaired site, but no information concerning laterality‚Äù|
|Grade Clinical (2018+)|Records the grade of a solid primary tumor before any treatment|1 = G1: Low combined histologic grade (favorable), SBR score of 3‚Äì5 points<BR>2 = G2: Intermediate combined histologic grade (moderately favorable); SBR score of 6‚Äì7 points<BR>3 = G3: High combined histologic grade (unfavorable); SBR score of 8‚Äì9 points<BR>L = Nuclear Grade I (Low) (in situ only)<BR>M = Nuclear Grade II (interMediate) (in situ only)<BR>H = Nuclear Grade III (High) (in situ only)<BR>A = Well differentiated<BR>B = Moderately differentiated<BR> C = Poorly differentiated<BR>D = Undifferentiated, anaplastic<BR>8 = Not applicable (Hematopoietic neoplasms only)<BR>9 = Grade cannot be assessed (GX); Unknown|Categorical: <BR>Low = 1, A, L<BR>Intermediate = 2, B, M<BR>High = 3, C, H, D<BR>*exclude N/A (8) and unknown (9)|
|ER Status Recode Breast Cancer (1990+)|Results of the estrogen receptor (ER) assay|Negative<BR>Positive<BR>Borderline/Unknown<BR>Recode not available|Binary: <BR>Negative<BR>Positive<BR>*exclude Borderline/Unknown, Recode not available|
|PR Status Recode Breast Cancer (1990+)|Results from the progesterone receptor (PR) assay|Negative<BR>Positive<BR>Borderline/Unknown<BR>Recode not available|Binary: <BR>Negative<BR>Positive<BR>*exclude Borderline/Unknown, Recode not available|
|HER2 Overall Summary Recode (2018+)|Summary of results from HER2 testing|HER2 negative; equivocal<BR>HER2 positive<BR>Test ordered, results not in chart<BR>Not documented; Cannot be determined; Not assessed or unknown if assessed|Binary: <BR>HER2 negative; equivocal<BR>HER2 positive<BR>*exclude Test ordered, results not in chart, Not documented; Cannot be determined; Not assessed or unknown if assessed|

Table 3

***Patient Demographics***

|Variable Name|Description|Seer Codes (2018-2022)|Recoding for modeling|
|:------|:------ |:------------|:------------|
|Age recode with <1 year olds|This data item represents the age of the patient at diagnosis for this cancer.|00 years <BR>01-04 years<BR>05-09 years<BR>10-14 years<BR>15-19 years<BR>20-24 years<BR>25-29 years <BR>30-34 years<BR>35-39 years<BR>40-44 years<BR>45-49 years <BR>50-54 years<BR>55-59 years<BR>60-64 years<BR>65-69 years<BR>70-74 years<BR>75-79 years<BR>80-84 years<BR>85+ years|Categorical: <BR>00 years <BR>01-04 years<BR>05-09 years<BR>10-14 years<BR>15-19 years<BR>20-24 years<BR>25-29 years <BR>30-34 years<BR>35-39 years<BR>40-44 years<BR>45-49 years <BR>50-54 years<BR>55-59 years<BR>60-64 years<BR>65-69 years<BR>70-74 years<BR>75-79 years<BR>80-84 years<BR>85+ years|"
|Sex|Male or Female|Male<BR>Female|Binary: <BR>Male <BR>Female|
|Race recode (W, B, AI, API)|Groups race into the following categories: White (W), Black (B), American Indian/Alaska Native (AI), and Asian/Pacific Islander (API)|White<BR>Black <BR>American Indian/Alaska Native<BR>Asian/Pacific Islander <BR>Unknown|Categorical: <BR>White<BR>Black <BR>American Indian/Alaska Native<BR>Asian/Pacific Islander <BR>Unknown|
|Origin recode NHIA (Hispanic, Non-Hisp)|Classifies cancer registry patients into one of two categories: Hispanic or Non-Hispanic, using the NAACCR Hispanic Identification Algorithm (NHIA)|Non-Spanish-Hispanic-Latino<BR>Spanish-Hispanic-Latino|Categorical: <BR>Non-Spanish-Hispanic-Latino<BR>Spanish-Hispanic-Latino|
|Race and origin recode (NHW, NHB, NHAIAN, NHAPI, Hispanic)|Combines race and Hispanic ethnicity for analysis, creating a single variable for Non-Hispanic White (NHW), Non-Hispanic Black (NHB), Non-Hispanic American Indian/Alaska Native (NHAIAN), Non-Hispanic Asian/Pacific Islander (NHAPI), and Hispanic (of any race) categories|Hispanic (All Races)<BR>Non-Hispanic White<BR>Non-Hispanic Black<BR>Non-Hispanic American Indian/Alaska Native<BR>Non-Hispanic Asian or Pacific Islander<BR>Non-Hispanic Unknown Race|Categorical: <BR>Non-Spanish-Hispanic-Latino<BR>Spanish-Hispanic-Latino|
|Marital status at diagnosis|Patient‚Äôs marital status at the time of diagnosis for the reportable tumor|Single (never married) <BR>Married (including common law)<BR>Separated<BR>Divorced<BR>Widowed<BR>Unmarried or Domestic Partner <BR>Unknown|Binary:<BR>Partnered = Married (including common law), Unmarried or Domestic Partner <BR>Unpartnered = Single (never married), Separated, Divorced, Widowed<BR>*exclude Unknown|
|Type of Reporting Source|Identifies the source documents that provided the most complete information when abstracting the case|Hospital inpatient/outpatient or clinic<BR>Radiation treatment or medical oncology center (2006+)<BR>Laboratory only (hospital or private)<BR>Physicians office/private medical practitioner (LMD)<BR>Nursing/convalescent home/hospice<BR>Autopsy Only<BR>Death Certificate Only<BR>Other hospital outpatient unit or surgery center (2006+)|Categorical: <BR>Hospital inpatient/outpatient or clinic<BR>Radiation treatment or medical oncology center (2006+)<BR>Laboratory only (hospital or private)<BR>Physicians office/private medical practitioner (LMD)<BR>Nursing/convalescent home/hospice<BR>Autopsy Only<BR>Death Certificate Only<BR>Other hospital outpatient unit or surgery center (2006+)|
|Year of Diagnosis|Cancers diagnosed from 2018-2022|2018<BR>2019<BR>2021<BR>2022|Categorical: <BR>2018<BR>2019<BR>2021<BR>2022|


## Methods

The basis for LASSO and Ridge regression is Ordinary Least Squares (OLS) regression. The objective of OLS regression is to minimize the sum of the squared residuals, which are the differences between the observed and predicted outcome values. The equation for OLS regression can be expressed as:

\begin{equation*} \hat{\beta}_{ols}=\underset{\beta}{\arg\min}\left\{\sum_{i=1}^{N}\left(y_{i}-\beta_{0}-\sum_{j=1}^{p}x_{ij}\beta_{j}\right)^{2}\right\} \tag{1} \end{equation*}

Where *N* is our number of observations, *p* is our number of parameters, *y~i~* is an observed outcome variable value, ùõΩ~0~ is the intercept, *ùë•~ij~* is an observed predictor variable value, and ùõΩ~ùëó~ is the coefficient for a parameter (Muthukrishnan and Rohini, 2016).

However, while OLS regression has low bias, it is also prone to overfitting and thus high variance. LASSO and Ridge regression remedy this by introducing a shrinkage parameter, denoted as ùúÜ. By shrinking the parameters, we introduce some bias but at the benefit of much lower variance.

For LASSO and Ridge regression, respectively, the basic OLS regression equation is modified to:

\begin{equation*} \hat{\beta}^{lasso}=\underset{\beta}{\arg\min}\left\{\frac{1}{2}\sum_{i=1}^{N}\left(y_{i}-\beta_{0}-\sum_{j=1}^{p}x_{ij}\beta_{j}\right)^{2}+\lambda\sum_{j=1}^{p}\left\vert\beta_{j}\right\vert\right\} \tag{2} \end{equation*}


\begin{equation*} \hat{\beta}^{ridge}=\underset{\beta}{\arg\min}\left\{\sum_{i=1}^{N}\left(y_{i}-\beta_{0}-\sum_{j=1}^{p}x_{ij}\beta_{j}\right)^{2}+\lambda\sum_{j=1}^{p}\beta_{j}^{2}\right\} \tag{3}\end{equation*}


where ùúÜ is the shrinkage parameter[@muthu]. Clearly, the higher the value of ùúÜ, the more the parameters are shrunken towards zero. Simply put, Ridge regression minimizes a combination of the sum of squared residuals and the shrinkage parameter times the squared sum of the parameters (L2-regularization), while LASSO regression minimizes a combination of the sum of squared residuals and the shrinkage parameter times the sum of the absolute values of the parameters (L1-regularization).

Of note, there exists an adaptation of the lasso regression created by Zou in 2006 called the ‚Äúadaptive lasso‚Äù. The ‚Äúadaptive lasso‚Äù penalized each parameter according to the importance, or weight, of its corresponding predictor variable. The adaptive lasso can be written as:

\begin{equation*} \hat{\beta}^{adaptive  lasso}=\underset{\beta}{\arg\min}\left\{\frac{1}{2}\sum_{i=1}^{N}\left(y_{i}-\beta_{0}-\sum_{j=1}^{p}x_{ij}\beta_{j}\right)^{2}+\lambda\sum_{j=1}^{p} w_{j}\left\vert\beta_{j}\right\vert\right\}\tag{4}\end{equation*}

where ùë§~ùëó~ is the weight assigned to a certain parameter[@vidaurre].

LASSO regression was selected to identify key predictors of treatment receipt (radiation and/or chemotherapy) among breast cancer patients. LASSO applies an L1 regularization penalty to the regression coefficients, shrinking less influential predictors toward zero while retaining the most relevant variables. This method is particularly appropriate for the SEER dataset which includes numerous clinical and demographic variables. Separate lasso models will be constructed for radiation and chemotherapy as binary outcome variables (1 = treatment received, 0 = not received/unknown). Predictors include the tumor characteristics and patient demographic variables.

## Analysis and Results

This analysis consisted of two Lasso regression models that were designed to identify the most influential predictors of first line radiation and chemotherapy use among breast cancer patients in the SEER dataset. These models were constructed with the goal of informing utilization management (UM) processes where expedited, evidence based approvals of treatments are essential for minimizing unnecessary delays in patient care. To prepare the data for modeling, all categorical variables were converted into a full model matrix using model.matrix( ) to ensure that the data was compatible with the regularization algorithm. The response variable (tv_radiation or tv_chemotherapy) was extracted as a separate numeric vector. 

The predictors were fitted to a wide range of Œª penalty values using the glmnet package with alpha = 1. Ten-fold cross validation was used (cv.glmnet()) to identify the Œª that minimized prediction error. By choosing the Œª that produced the best performing model, the analysis ensured that the predictive patterns were both statistically sound and clinically meaningful and generalizable. Generalizability is an important requirement for UM applications that rely on models that remain stable across diverse patient populations. 

```{r}
library(data.table)
library(ISLR2)
library(glmnet)
library(dplyr)
library(tidyr)
```

### Radiation prediction data

```{r}
#datar <- fread("/Users/vmohanam/Downloads/data/Selected_var_formated.csv")

data_rad = na.omit(fread("/Users/vmohanam/Downloads/data/Selected_var_formated_rad.csv"))
#str(data)
x = model.matrix(tv_radiation~., data_rad)[,-1] 
y = data_rad %>%
  select(tv_radiation) %>%
  unlist() %>%
  as.numeric()
#hist(data$tv_radiation)
hist(data_rad$pd_year_of_diagnosis)

```

```{r}
grid = 10^seq(-30, 10, length = 100)
lasso_fit = glmnet(x, y, alpha = 1, lambda = grid, standardize = TRUE, nfolds = 10)

plot(lasso_fit)
#find the best CV lambda
lambda_cv <- lasso_fit$lambda.min

# Best cross-validated lambda

# Fit final model, get its sum of squared residuals and multiple R-squared
model_cv <- glmnet(x, y, alpha = 1, lambda = lambda_cv, standardize = TRUE)
y_hat_cv <- predict(model_cv, x)
ssr_cv <- t(y - y_hat_cv) %*% (y - y_hat_cv)
rsq_lasso_cv <- cor(y, y_hat_cv)^2
#rsq_lasso_cv

# See how increasing lambda shrinks the coefficients --------------------------
# Each line shows coefficients for one variables, for different lambdas.
# The higher the lambda, the more the coefficients are shrinked towards zero.
res <- glmnet(x, y, alpha = 1, lambda = grid, standardize = FALSE)
plot(res, xvar = "lambda")
legend("bottomright", lwd = 1, col = 1:6, legend = colnames(x), cex = .7)
title ("Radiation Model")

```

```{r}
set.seed(1)
cv.out = cv.glmnet(x, y, alpha = 1, standardize = TRUE, nfolds = 10) 
plot(cv.out) 
bestlam = cv.out$lambda.min 
coef(cv.out, s=bestlam)
```


### Chemotherapy prediction data

```{r}
# for chemotheraphy
data_che = na.omit(fread("/Users/vmohanam/Downloads/data/Selected_var_formated_che.csv"))
#str(data)
x2 = model.matrix(tv_chemotherapy~., data_che)[,-1] 
y2 = data_che %>%
  select(tv_chemotherapy) %>%
  unlist() %>%
  as.numeric()
#hist(data$tv_radiation)
hist(data_che$pd_age)

```

```{r}
#grid = 10^seq(-30, 10, length = 100)
lasso_fit2 = glmnet(x2, y2, alpha = 1, lambda = grid, standardize = TRUE, nfolds = 10)

plot(lasso_fit2)
#find the best CV lambda
lambda_cv2 <- lasso_fit2$lambda.min

# Best cross-validated lambda

# Fit final model, get its sum of squared residuals and multiple R-squared
model_cv2 <- glmnet(x2, y2, alpha = 1, lambda = lambda_cv2, standardize = TRUE)
y_hat_cv2 <- predict(model_cv2, x2)
ssr_cv2 <- t(y2 - y_hat_cv2) %*% (y2 - y_hat_cv2)
rsq_lasso_cv2 <- cor(y2, y_hat_cv2)^2
#rsq_lasso_cv

# See how increasing lambda shrinks the coefficients --------------------------
# Each line shows coefficients for one variables, for different lambdas.
# The higher the lambda, the more the coefficients are shrinked towards zero.
res2 <- glmnet(x2, y2, alpha = 1, lambda = grid, standardize = FALSE)
plot(res2, xvar = "lambda")
legend("bottomright", lwd = 1, col = 1:6, legend = colnames(x2), cex = .7)
title ("Chemotherapy Model")
```

```{r}
set.seed(1)
cv2.out = cv.glmnet(x2, y2, alpha = 1, standardize = TRUE, nfolds = 10) 
plot(cv2.out) 
bestlam2 = cv2.out$lambda.min 
coef(cv2.out, s=bestlam2)
```
## Modeling and Results

***Radiation Treatment Model***

The cross- validation procedure selected an optimal penalty value of Œª = 0.000148. There were two predictors that shrunk to zero (lung metastasis and distant disease). Because only 2 predictors went to zero this suggests that most predictors have some influence on radiation therapy treatment decisions. The following subset of the 18 remaining predictors that kept non-zero coefficients that were > 0.05 are shown in Table 4. 

Table 4

|Variable|Coefficient|Interpretation|
|:------|:------ |:------------|
|Age|0.123|Increased age had a slight increase in radiation likelihood|
|Sex|-0.082|Male patients slightly less likely to receive radiation|
|Grade|0.203|HIgher grade tumor more likely to get radiation|
|Brain metastasis|0.104|Brain involvement increases radiation likelihood|
|HER2 status (+)|0.452|HER2+ patients more likely to get radiation|
|ER status (+)|-0.253|ER+ patients less likely to get radiation|
|PR status (+)|-0.153|PR+ patients less likely to get radiation|
|Tumor size|0.184|Larger tumors increase radiation likelihood|
|Node status|0.221|Node positive patients more likely to get radiation|
|Histology type|0.081|Specific histology types are more likely to get radiation|

<BR>
***Chemotherapy Treatment Model***

The cross- validation procedure selected an optimal penalty value of Œª = 0.0005029. There were five predictors that shrunk to zero (bone metastasis, liver metastasis, lung metastasis, laterality and distant disease). More predictors in the chemotherapy model shrunk to zero indicating that more had a negligible predictive power. The following subset of the 15 remaining predictors that kept non-zero coefficients that were > 0.05 are shown in Table 5. 

Table 5

|Variable|Coefficient|Interpretation|
|:------|:------ |:------------|
|Age|-0.054|Increased age had a slight decrease in chemotherapy likelihood|
|Sex|-0.102|Male patients less likely to receive chemotherapy|
|Grade|0.248|HIgher grade tumor more likely to get chemotherapy|
|Brain metastasis|0.118|Brain involvement increases chemotherapy likelihood|
|HER2 status (+)|0.382|HER2+ patients more likely to get chemotherapy|
|ER status (+)|-0.303|ER+ patients less likely to get chemotherapy|
|PR status (+)|-0.178|PR+ patients less likely to get chemotherapy|
|Tumor size|0.201|Larger tumors increase chemotherapy likelihood|
|Node status|0.282|Node positive patients more likely to get chemotherapy|
|Histology type|0.102|Specific histology types are more likely to get chemotherapy|

## Implications

The results from both Lasso regression models directly support the problem at hand of creating tools that can improve utilization management workflows and accelerate treatment approvals for breast cancer patients. By clearly identifying clinical factors most strongly associated with providers treatment decisions, the models offer a data driven method to anticipate which treatments are likely appropriate for a given patient's specific disease characteristics. This type of predictive insight can help UM reviewers move away from manual case-by-case review and toward automated or semi-antimated pathways that approve treatments when the clinical features strongly match established patterns.

The radiation model showed that higher tumor grade, larger tumor size and regional (node) involvement substantially increased the likelihood of receiving radiation therapy. This aligns with standard oncology practice and can be leveraged within utilization management (UM) systems to expedite approval for patients whose clinical profiles match these evidence-supported indicators. The model also indicated that ER+ and PR+ patients were less likely to receive radiation, while HER2+ status and brain metastasis increased likelihood, highlighting the nuanced role of tumor biology in treatment decisions. Recognizing these distinctions allows UM reviewers to quickly assess whether a requested radiation treatment aligns with expected care patterns.

The chemotherapy model also identified strong and clinically meaningful predictors. Higher tumor grade, larger tumor size, node involvement and HER2+ status significantly increased the likelihood of chemotherapy, supporting rapid UM approval for patients with these characteristics. In contrast, ER+ and PR+ status, older age and male sex were associated with decreased chemotherapy likelihood, consistent with hormonal based treatment plans and real-world guideline supported treatments. Brain metastasis and histology type also contributed to treatment predictions. By translating these predictive features into structured UM rules or automated decision-support tools, healthcare organizations can reduce manual review time, minimize administrative burden and accelerate approval for medically necessary treatments while ensuring alignment with evidence-based care.

Traditional logistic regression may have been prone to overfitting due to the high correlation between tumor characteristics such as stage, tumor size, nodal involvement and metastatic indicators. Lasso regression was able to address these limitations by shrinking weaker predictors towards zero and retaining only the variables with the strongest independent predictors to treatment decisions. These results provided a narrowed down and informative set of predictors to allow for clear interpretations and a process for applying these findings to real-world utilization management scenarios.  

Interestingly, the models for both radiation and chemotherapy highlight the same set of 10 predictors with coefficients above 0.05. This overlap suggests that a common subset of patient and tumor characteristics consistently influence treatment decisions. The shared importance of these variables emphasizes their strong clinical relevance and indicates that, in this group of first line patients, similar factors are driving the likelihood of receiving either radiation or chemotherapy. 

While it may seem obvious that factors such as age, sex, tumor grade, tumor size, node status, HER2, ER and PR status, histology type and brain metastasis would influence treatment decisions. The overlap between the radiation and chemotherapy models demonstrates that multiple variables collectively drive these decisions rather than any single factor alone. Identifying this set of clear, high-impact predictors is valuable because it provides a structured framework that could be translated into a standardized question set for use in utilization management. By systematically capturing these key predictors, clinicians and reviewers can more efficiently evaluate patient cases and expedite treatment recommendations and approvals. 


## Conclusion

  In this study, we applied Lasso regression to real-world health care data using the Surveillance, Epidemiology, and End Results (SEER) database. Specifically, we focused on breast cancer in women during the years 2018-2022. We estimated the likelihood of both radiation therapy and chemotherapy treatment variables based on various tumor characteristic variables and patient demographic variables.

  Using cross-validation for the radiation treatment model, we obtained a shrinkage parameter, Œª = 0.000148. Using cross-validation for the chemotherapy treatment model, we obtained a Œª = 0.0005029. For the radiation treatment model, we were only able to shrink two parameters to zero: metastasis to lungs and metastasis to distant lymph nodes. For the chemotherapy treatment model, we were able to shrink five parameters to zero: metastasis to bone, metastasis to lungs, metastasis to distant lymph nodes, and laterality. It makes sense that we were able to shrink more parameters to zero with the chemotherapy model versus the radiotherapy model. This is very likely because the chemotherapy model‚Äôs shrinkage parameters was over threefold higher than the radiotherapy model‚Äôs shrinkage parameter.
  
  There were some coefficients for both the radiotherapy and chemotherapy models that did not shrink to zero, but had an absolute value lower than 0.05. For non-zero coefficients with an absolute value lower than 0.05, we took these out of our final Lasso model. In the radiotherapy final model, we found that age, tumor grade, tumor size, node positive status, brain metastasis, positive HER2 receptor status, and specific histology types are all associated with a higher likelihood of getting radiation therapy. Meanwhile, male sex, positive estrogen receptor (ER) status, and positive progesterone receptor (PR) status are all associated with a lower likelihood for radiation therapy. In the chemotherapy final model, we found that tumor grade, tumor size, node positive status, brain metastasis, positive HER2 receptor status, and histology type were all associated with a higher likelihood of receiving chemotherapy. Meanwhile, age, male sex, positive ER status, and positive PR status were all associated with a lower likelihood for chemotherapy.
  
  Overall, this study is significant because it suggests that we can look at many patient demographic and clinical tumor variables to evaluate the best treatment options for patients. Every unique patient possesses their own unique demographics and clinical markers. By looking at these many unique variables, we can create a model that finds the optimal patient treatment method for a patient and facilitates the ability of clinicians to create individualized treatment plans. For future studies, we can find another dataset that contains a different set of variables. We can then use Lasso regression, as we did here, to model how these new variables correlate with different treatment options.


## References

